浸润性膀胱癌根治性治疗后的监测策略。
Surveillance strategies after definitive therapy of invasive bladder cancer.
作者信息
Cagiannos Ilias, Morash Christopher
机构信息
Division of Urology, University of Ottawa, Ottawa, ON.
出版信息
Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S237-42. doi: 10.5489/cuaj.1205.
Abstract
Following definitive therapy for muscle invasive bladder cancer, patients remain at risk for local and distant recurrence. Additionally, recurrences can result from formation of new tumours elsewhere in the urinary tract. We review patterns of recurrence and the prognosis associated with recurrence. Optimal surveillance strategies are discussed.
摘要
在接受肌肉浸润性膀胱癌的确定性治疗后，患者仍有局部和远处复发的风险。此外，复发可能源于尿路其他部位新肿瘤的形成。我们回顾了复发模式以及与复发相关的预后情况。并讨论了最佳监测策略。
相似文献
1
Surveillance strategies after definitive therapy of invasive bladder cancer.
Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S237-42. doi: 10.5489/cuaj.1205.
2
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience.
BJU Int. 2012 Nov;110(9):1317-23. doi: 10.1111/j.1464-410X.2012.11133.x. Epub 2012 Apr 13.
3
Commentary on "Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience." Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W. Department of Surgery (Urology), McGill University, Quebec, Canada: BJU Int 2012;110(9):1317-23 [Epub 2012 Apr 13].
Urol Oncol. 2013 Jul;31(5):717-8. doi: 10.1016/j.urolonc.2013.03.011.
4
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
5
Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection.
Chin Med J (Engl). 2012 Oct;125(20):3681-6.
6
Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Urol Oncol. 2013 Nov;31(8):1615-20. doi: 10.1016/j.urolonc.2012.03.004. Epub 2012 Apr 21.
7
Upper urinary tract recurrence following bladder cancer therapy: a review of surveillance and management.
Curr Opin Urol. 2019 May;29(3):189-197. doi: 10.1097/MOU.0000000000000598.
8
The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
BJU Int. 2004 Dec;94(9):1258-62. doi: 10.1111/j.1464-410X.2004.05228.x.
9
Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma.
Curr Opin Urol. 2015 Sep;25(5):468-75. doi: 10.1097/MOU.0000000000000201.
10
Management of local recurrences in the irradiated bladder: a systematic review.
BJU Int. 2012 Dec;110 Suppl 4:51-7. doi: 10.1111/j.1464-410X.2012.11476.x.
引用本文的文献
1
Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated With Nivolumab.
JAMA Netw Open. 2025 Jun 2;8(6):e2514427. doi: 10.1001/jamanetworkopen.2025.14427.
2
Plasma-Derived Cell-Free DNA as a Biomarker for Early Detection, Prognostication, and Personalized Treatment of Urothelial Carcinoma.
J Clin Med. 2024 Apr 2;13(7):2057. doi: 10.3390/jcm13072057.
3
Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma.
Curr Oncol Rep. 2024 May;26(5):496-503. doi: 10.1007/s11912-024-01523-8. Epub 2024 Apr 11.
4
Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.
Investig Clin Urol. 2023 May;64(3):202-218. doi: 10.4111/icu.20230006.
5
Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.
World J Urol. 2023 Apr;41(4):1069-1075. doi: 10.1007/s00345-023-04335-w. Epub 2023 Mar 16.
6
Imaging Tips and Tricks in Management of Renal and Urothelial Malignancies.
Indian J Radiol Imaging. 2022 Jul 5;32(2):213-223. doi: 10.1055/s-0042-1744520. eCollection 2022 Jun.
7
Transitional cell carcinoma recurrence impacting intestinal diversion after radical cystectomy. Oncologic outcomes of a rare site of recurrence.
Cent European J Urol. 2020;73(4):445-456. doi: 10.5173/ceju.2020.0168.R1. Epub 2020 Dec 9.
8
Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer.
Can Urol Assoc J. 2020 Apr;14(4):122-129. doi: 10.5489/cuaj.5945. Epub 2019 Nov 5.
9
Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.
Transl Androl Urol. 2017 Dec;6(6):1081-1089. doi: 10.21037/tau.2017.08.19.
10
Rare Occurrence of a Poorly Differentiated Neuroendocrine Tumor of the Bladder.
Case Rep Med. 2017;2017:4812453. doi: 10.1155/2017/4812453. Epub 2017 Jan 2.
本文引用的文献
1
Oncological followup after radical cystectomy for bladder cancer-is there any benefit?
J Urol. 2009 Apr;181(4):1587-93; discussion 1593. doi: 10.1016/j.juro.2008.11.112. Epub 2009 Feb 23.
2
Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
BJU Int. 2008 Nov;102(9 Pt B):1345-53. doi: 10.1111/j.1464-410X.2008.07981.x.
3
Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance.
J Urol. 2008 Jan;179(1):96-100. doi: 10.1016/j.juro.2007.08.131. Epub 2007 Nov 13.
4
Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature.
J Urol. 2007 Sep;178(3 Pt 1):756-60. doi: 10.1016/j.juro.2007.05.013. Epub 2007 Jul 13.
5
Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
J Urol. 2007 Jun;177(6):2088-94. doi: 10.1016/j.juro.2007.01.133.
6
Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments.
BJU Int. 2007 Jul;100(1):11-6. doi: 10.1111/j.1464-410X.2007.06841.x. Epub 2007 Apr 8.
7
Tumor recurrence in the remnant urothelium of females undergoing radical cystectomy for transitional cell carcinoma of the bladder: long-term results from a single center.
J Urol. 2006 Apr;175(4):1268-71; discussion 1271. doi: 10.1016/S0022-5347(05)00643-9.
8
Cancer statistics, 2005.
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30. doi: 10.3322/canjclin.55.1.10.
9
Upper tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: incidence and risk factors.
BJU Int. 2004 Oct;94(6):785-9. doi: 10.1111/j.1464-410X.2004.05032.x.
10
The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer.
J Urol. 2004 Oct;172(4 Pt 1):1342-7. doi: 10.1097/01.ju.0000138208.07426.19.
Zotero 插件